Liberty Macias
Psychiatric/Mental Health · Redlands, CANPI 1376936476
Payments from drug & device makers
Across 1,196 payments — averaging $240.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alkermes, Inc.$74K
- Teva Pharmaceuticals USA, Inc.$74K
- E.r. Squibb & Sons, L.L.C.$35K
- Neurocrine Biosciences, Inc.$28K
- AbbVie$27K
- Axsome Therapeutics, Inc.$21K
- plus $30K from 19 others
What the payments were for
- Consulting fees$17,1146%
- Speaking & faculty fees$214,34074%
- Travel & lodging$26,5979%
- Food & beverage$29,81810%
- Education$3420%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alkermes, Inc. | 177 | $74,169 |
| Teva Pharmaceuticals USA, Inc. | 211 | $73,559 |
| E.r. Squibb & Sons, L.L.C. | 65 | $34,619 |
| Neurocrine Biosciences, Inc. | 49 | $27,919 |
| AbbVie(2 entities) | 159 | $26,734 |
| Axsome Therapeutics, Inc. | 63 | $21,136 |
| Idorsia Pharmaceuticals US Inc | 35 | $8,944 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 21 | $7,275 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 42 | $5,837 |
| Otsuka America Pharmaceutical, Inc. | 126 | $2,853 |
| Johnson & Johnson | 32 | $920 |
| Lundbeck LLC | 50 | $748 |
| Vanda Pharmaceuticals Inc. | 21 | $714 |
| Takeda Pharmaceuticals U.S.A., Inc. | 36 | $582 |
| Sunovion Pharmaceuticals Inc. | 38 | $572 |
| Almatica Pharma LLC | 26 | $458 |
| Indivior Inc. | 19 | $388 |
| Corium, LLC | 6 | $227 |
| Eisai Inc. | 5 | $181 |
| Noven Therapeutics, LLC | 6 | $127 |
| Lilly USA, LLC | 1 | $125 |
| Avanir Pharmaceuticals, Inc. | 4 | $60 |
| Supernus Pharmaceuticals, Inc. | 2 | $27 |
| Luye Pharma (USA) Ltd. | 1 | $20 |
| Tris Pharma Inc | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$288,210 in reported general payments places this provider in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 34 | $208,792 |
| IngrezzaValbenazine Tosylate | 24 | $180,064 |
| LybalviOlanzapine/Samidorphan Malate | 54 | $91,571 |
| RexultiBrexpiprazole | 32 | $64,030 |
| AuvelityDextromethorphan Hbr/Bupropion | 47 | $48,720 |
| CaplytaLumateperone Tosylate | 27 | $43,827 |
| Invega SustennaPaliperidone Palmitate | 12 | $40,265 |
| QuviviqDaridorexant Hcl | 47 | $22,648 |
| VraylarCariprazine Hcl | 16 | $22,226 |
| TrintellixVortioxetine Hydrobromide | 40 | $22,201 |
| SecuadoAsenapine | 11 | $14,651 |
| Lurasidone Hcl | 26 | $5,478 |
| DayvigoLemborexant | 13 | $4,185 |
| Quetiapine Fumarate | 112 | $1,229 |
| Trazodone Hcl | 164 | $1,202 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $73,559 | $208,79234 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $27,919 | $180,06424 claims |
| Alkermes, Inc.Lybalvi | $74,169 | $91,57154 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,853 | $64,03032 claims |
| Axsome Therapeutics, Inc.Auvelity | $21,136 | $48,72047 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $5,837 | $43,82727 claims |
| Johnson & JohnsonInvega Sustenna | $920 | $40,26512 claims |
| Idorsia Pharmaceuticals US IncQuviviq | $8,944 | $22,64847 claims |
| AbbVieVraylar | $26,734 | $22,22616 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $582 | $22,20140 claims |
| Eisai Inc.Dayvigo | $181 | $4,18513 claims |
| Lilly USA, LLCOlanzapine | $125 | $41048 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,433 psychiatric/mental health providers in California.
Other psychiatric/mental health in Redlands
- John AdenijiRedlands$29K
- Magnus IhemeduRedlands$15K
- Jogendra SinghRedlands$14K
- Akta PatelRedlands$11K
- Linda JacksonRedlands$11K
- Carey MartinMillbrae$745K
- Joshua BurgettSacramento$239K
- Jovita Ezirim-SalamialofojeLos Angeles$162K
- Angie-Kolleen TanThousand Oaks$159K
- Thy LamVista$121K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.